The area surrounding the injured spinal cord is a non-permissive milieu for axonal growth due to the inhibitory factors, especially chondroitin sulfate proteoglycan (CSPG) and Nogo. Recent studies have reported that chondroitinase ABC (ChABC) or Nogo-66(1-40) antagonist peptide (NEP1-40) promote axonal growth after spinal cord injury. But no study has addressed the effects on spinal cord injury of combining ChABC and NEP1-40. Previously, we described an organotypic co-culture system using the brain cortex and spinal cord from neonatal rats. In this study, we examined whether the combination of ChABC and NEP1-40 creates an action that promotes corticospinal axon growth in organotypic co-cultures. Organotypic co-cultures of brain and spinal cord were prepared from rats, and ChABC or NEP1-40 was delivered to them. To examine the effects of this combination these two drugs were applied together. We counted the number of labeled axons with DiI and assessed the immunoreactivity of CSPG and Nogo. Axonal growth was enhanced by infusing ChABC or NEP1-40 compared with that in the control group, whereas synergistic effects of combined administration of ChABC and NEP1-40 on axonal growth were not observed. There is a possibility that ChABC and NEP1-40 affect the same intracellular pathways and have no synergistic influence on axonal growth.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neulet.2010.03.049DOI Listing

Publication Analysis

Top Keywords

chabc nep1-40
24
spinal cord
20
axonal growth
20
organotypic co-cultures
12
chondroitinase abc
8
nep1-40
8
corticospinal axon
8
axon growth
8
growth organotypic
8
cspg nogo
8

Similar Publications

Sustained dual drug delivery of anti-inhibitory molecules for treatment of spinal cord injury.

J Control Release

September 2015

Department of Biomedical Engineering, Washington University, St. Louis, MO 63130, United States. Electronic address:

Myelin-associated inhibitors (MAIs) and chondroitin sulfate proteoglycans (CSPGs) are major contributors to axon growth inhibition following spinal cord injury and limit functional recovery. The NEP1-40 peptide competitively binds the Nogo receptor and partially blocks inhibition from MAIs, while chondroitinase ABC (ChABC) enzymatically digests CSPGs, which are upregulated at the site of injury. In vitro studies showed that the combination of ChABC and NEP1-40 increased neurite extension compared to either treatment alone when dissociated embryonic dorsal root ganglia were seeded onto inhibitory substrates containing both MAIs and CSPGs.

View Article and Find Full Text PDF

The effects of combining chondroitinase ABC and NEP1-40 on the corticospinal axon growth in organotypic co-cultures.

Neurosci Lett

May 2010

Department of Orthopaedic Surgery, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.

The area surrounding the injured spinal cord is a non-permissive milieu for axonal growth due to the inhibitory factors, especially chondroitin sulfate proteoglycan (CSPG) and Nogo. Recent studies have reported that chondroitinase ABC (ChABC) or Nogo-66(1-40) antagonist peptide (NEP1-40) promote axonal growth after spinal cord injury. But no study has addressed the effects on spinal cord injury of combining ChABC and NEP1-40.

View Article and Find Full Text PDF

Damaged axons do not regenerate after axotomy in the adult mammalian central nervous system (CNS). This may be due to local inhibitory factors at the site of injury, such as overexpression of chondroitin sulfate (CS) proteoglycans (CSPG), and the presence of myelin-associated inhibitors (MAI). To overcome CSPG- or myelin-induced inhibition, strategies based on extrinsic and intrinsic treatments have been developed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!